UTI Healthcare Fund · Regular · Growth
NAV
₹339.2556
as of 28 Sept 2026
Expense Ratio
2.21%
AUM
₹1,181 Cr
Lumpsum returns (CAGR)
- 1Y
- +18.95%
- 3Y
- +22.24%
- 5Y
- +14.81%
- Since Inception
- +13.19%
SIP returns (XIRR)
- 1Y
- +25.86%
- 3Y
- +18.41%
- 5Y
- +20.19%
- Since Inception
- +15.41%
Returns calculated from 16 September 2014 onwards due to a structural change in the scheme on that date. Earlier NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
What history actually did — last 10 years (Sept 2016 – Sept 2026)
A ₹5,000 monthly SIP for the last 10 years (Sept 2016 – Sept 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹15,65,815 today — ₹6,00,000 invested, 18.3% XIRR.
₹6,00,000
Invested
₹15,65,815
Value today
18.3%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Sept 2016 – Sept 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹3,63,672 today (13.8% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Sept 2016 would still hold ₹20,70,903.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹15,65,815 in this fund vs ₹11,47,923 in the benchmark — outperformance of ₹4,17,892.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Sept 2016 – Sept 2026) (22 Mar 2020) would be ₹4,59,736 today (4.60×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised1.21
Sharpe Ratio
+0.22
Alpha
0.20
Beta
1.20
Sortino
12.43%
Std Dev
-10.39%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Aug 2026- Pharmaceuticals & Biotechnology67.86%
- Healthcare Services23.98%
- Chemicals & Petrochemicals1.42%
- Healthcare Equipment & Supplies0.98%
Each sector links to the mutual funds most exposed to it.
Related reading
Thinking about UTI Healthcare Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Sun Pharmaceuticals Industries8.25%
- 2Divis Laboratories Ltd.6.21%
- 3Ajanta Pharma Ltd.4.74%
- 4Gland Pharma Ltd.3.70%
- 5Dr Reddys Laboratories Ltd.3.62%
- 6Alkem Laboratories Ltd3.29%
- 7Apollo Hospitals Enterprise Lt3.27%
- 8Max Healthcare Institute Ltd3.10%
- 9Lupin Ltd.3.09%
- 10Caplin Point Laboratories Ltd3.05%
What this fund does
UTI Healthcare Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
UTI Healthcare Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by UTI Mutual Fund. The fund has been operational for over 27 years. It manages assets worth ₹1,181 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE Healthcare TRI. The current expense ratio is 2.21%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations